Posts by: Marisa Wexler, MS

Marisa Wexler, MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

May 11, 2020May 11, 2020

At-home System of Inhaled Nitric Oxide Treats PAH Patient Infected With COVID-19

News, PAH News

At-home treatment with inhaled nitric oxide through Genosyl, a tankless delivery system, was used successfully to manage pulmonary arterial hypertension (PAH) complicated by COVID-19 in a patient, according to a ... Read more

May 1, 2020May 1, 2020

LIQ861, Inhaled Form of Treprostinil, Fares Well in Phase 3 Trial for PAH

News

LIQ861, Liquidia Technology‘s investigational inhaled formulation of treprostinil, is safe and well-tolerated in patients with pulmonary arterial hypertension (PAH), according to final results from a Phase 3 clinical trial. ... Read more

April 29, 2020April 29, 2020

Pulmonary Hypertension Association to Hold Virtual Fundraiser on World PH Day

News, PH News

The Pulmonary Hypertension Association (PHA) will be participating in a fundraiser for World PH Day on May 5. World PH Day is an annual event that started in 2012 ... Read more

April 1, 2020April 1, 2020

Reata Stops Bardoxolone PAH Trials Amid COVID-19 Concerns

News, PAH News

Reata Pharmaceuticals is stopping clinical trials evaluating bardoxolone methyl in people with pulmonary arterial hypertension (PAH), including a Phase 3 study, to ensure the safety of participants during the ... Read more

March 25, 2020March 25, 2020

COVID-19 Patient with PH Treated with iNO Via Genosyl, VERO Biotech Announces

News, PH News

The first person with coronavirus disease 2019 (COVID-19) complicating pulmonary hypertension (PH) has received at-home treatment with inhaled nitric oxide (iNO), delivered through the Genosyl system, according to VERO Biotech, manufacturer ... Read more

March 20, 2020March 20, 2020

Orenitram Tablets More Cost-effective Than Uptravi as PAH Treatment, Study Suggests

News, PAH News

Treatment with Orenitram (oral treprostinil) is associated with lower healthcare-related costs than treatment with Uptravi (selexipag) in people with pulmonary arterial hypertension (PAH), a new study suggests. The study, “Medication Adherence ... Read more

March 18, 2020March 19, 2020

Major Bleed Risk Higher With Warfarin Than Xarelto in CTEPH Patients, Study Finds

CTEPH News, News

Among people with chronic thromboembolic pulmonary hypertension (CTEPH), certain anticoagulants may reduce the risk of serious bleeding more than others, a new study shows. The study, “Real-life data of ... Read more

March 13, 2020March 13, 2020

Bellerophon, FDA Agree on Design of Phase 3 INOPulse Clinical Trial

News, PH News

Bellerophon Therapeutics has reached an agreement with the U.S. Food and Drug Administration (FDA) setting the design of an upcoming, pivotal Phase 3 clinical trial testing INOpulse, an investigational ... Read more

February 24, 2020February 24, 2020

Using INOpulse Nitric Oxide Device Improves Blood Flow in Lungs in PH-PF, New Trial Data Suggest

News, PH News

Use of Bellerophon Therapeutics’ INOpulse device — which provides nitric oxide to the lungs — significantly improved parameters related to blood flow in the lungs in people with pulmonary ... Read more

February 17, 2020February 17, 2020

Case Report Suggests Lack of Vitamin C as PAH Cause

News, PAH News

Vitamin C deficiency can cause pulmonary arterial hypertension (PAH), a new case report suggests, highlighting the need to test vitamin C levels in people with PAH. The report, “Vitamin ... Read more

Pin It on Pinterest